BIRC3 and breast carcinoma: Moreover, in breast cancer cells exhibiting high sensitivity to IL-1β, stimulation with IL-1β markedly induces the upregulation of BIRC3 expression, consequently conferring resistance to doxorubicin treatment (Rho et al., 2022).